EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures
12.9.2024 18:00:00 CEST | Business Wire | Press release
EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Michel Detheux Ph.D, as Chairman of the Board and Independent Board Member, and Mojgan Hossein-Nia as Director representative of Takeda Ventures.
“We are thrilled to welcome Michel Detheux and Mojgan Hossein-Nia to our Board of Directors. Michel and Mojgan’s expertise and outstanding track record will be invaluable to Egle as we advance our clinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer and autoimmune diseases.Their expertise in the field of oncology and their experience are instrumental for us to successfully execute on our strategic priorities,” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member.
“With the role of regulatory T cells becoming clearer in oncology and auto-immunity, I am excited to join the Board of Egle in order to help the team to move their differentiated pipeline toward a clinical proof of concept and help patients with innovative drugs targeting IL-2,” said Michel Detheux, independent chairman at Egle and CEO of iTeos Therapeutics.
“I am excited to join the Board of Egle in order to help the team strategize and continue to advance their pipeline to help patients in areas of unmet needs,” said Mojgan Hossein-Nia, Board Member at Egle Therapeutics.
Michel Detheux, Ph.D, Michel has held the role of Chief Executive Officer at iTeos Therapeutics since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).
Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School.
Mojgan Hossein-Nia, Ph.D., Mojgan is the Head of R&D Global Portfolio Strategy and Strategic Finance, Research and Development at Takeda. She joined the company in September 2017 and currently directs portfolio strategy and management across all therapeutic areas facilitating investment decisions and overseeing R&D governance process. Additionally, she manages enabling capabilities that support portfolio management including the center of operational performance and integrated portfolio/finance digital solutions. In previous roles, she led the R&D investor relations group and built up the R&D Partnership Office, which was created to manage the overall health of R&D’s pipeline partnerships and their integration into R&D processes.
Before joining Takeda, Mojgan worked at Novartis Pharmaceuticals, building and leading multiple global functions across R&D. Mojgan’s career spans over 30 years, comprising dedicated roles in development outsourcing, global program leadership and project management, business development & licensing, and across multiple therapeutic areas including cardiovascular, metabolism, and cell & gene therapies.
Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from University of London, UK, and a diploma in pharmaceutical medicine from University of Surrey, UK.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912516511/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gaétane Baudry Appointed Senior Vice President/Global General Manager, Bobbi Brown8.10.2026 14:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Gaétane Baudry as Senior Vice President/Global General Manager, Bobbi Brown, effective October 8, 2026. Based in New York, she will report to Lisa Sequino, Global President, Makeup Brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008525584/en/ Gaétane Baudry In this role, Gaétane will lead Bobbi Brown’s global strategy and continued evolution, strengthening the brand’s distinctive equity, advancing innovation and creativity, and deepening consumer engagement around the world. “Gaétane is an inspiring and highly collaborative leader who brings experience, energy and a strong focus on execution,” said Lisa Sequino, Global President, Makeup Brands. “Her global brand-building record, strong commercial leadership and passion for creating meaningful consumer experiences will be invaluable as Bobbi Brown builds on its unique brand equity focused
Adtran launches Mosaic One Agents to help teams easily scale operations8.10.2026 14:00:00 CEST | Press release
News summary: Rapidly growing networks, operations and customer demands call for new ways to scale expertise Mosaic One Agents provides role-specific AI agent teams for network management, customer care and business operations Agent teams use data from Adtran and third-party hardware to investigate problems in parallel while organizations retain control Adtran today launched Mosaic One Agents, a suite of AI agents designed to help organizations scale expertise across network management, customer care and business operations. Built on Mosaic One Fabric, it gives role-based agent teams access to data from Adtran and third-party networks, enabling them to investigate issues, coordinate work across teams and drive issues through to resolution. By handling time-consuming investigation, coordination and process tasks, Mosaic One Agents helps people resolve issues faster, extend their expertise across more workflows and retain control of critical network and business actions. “When something
The LYCRA Company to Spotlight Renewable LYCRA® Fiber and Textile-to-Textile Circularity at Textile Exchange Conference 20268.10.2026 14:00:00 CEST | Press release
The LYCRA Company, a global leader in fiber and technology solutions for the apparel and personal care industries, will showcase Renewable LYCRA® fiber and its work to advance textile-to-textile recycling at Textile Exchange Conference 2026. The conference takes place October 12–16, at the Vancouver Convention Centre in Vancouver, Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008178765/en/ At the Textile Exchange Conference 2026, The LYCRA Company will showcase Renewable LYCRA® fiber and its progress in advancing textile-to-textile recycling. This year's theme, "The Implementation Era," focuses on scaling what works across businesses, supply systems, and landscapes. At the conference, The LYCRA Company will highlight its work with partners across the value chain, helping to shape the future for textiles through renewable fiber solutions, circular innovation, and strategic industry partnerships. “Bringing more rec
ARIS Strengthens Global Leadership Team with Three Senior Appointments to Accelerate 2027 Growth8.10.2026 14:00:00 CEST | Press release
Process Context Platform for Enterprise AI adds new Chief Product Officer, Global Head of Strategy & Transformation and Americas sales lead to help capitalize on growing enterprise demand for trusted, scalable AI ARIS, the global leader in Process Context for Enterprise AI, today announced three new senior appointments as it builds momentum toward 2027 and accelerates its strategy to help organizations put AI to work at scale. Maxime Hambersin joins as Chief Product Officer, Dr. Benjamin Krusche as Global Head of Strategy & Transformation, and Mark Jacobs as President and Go-to-Market Lead, Americas. The appointments further strengthen the leadership team built around CEO Guillaume Bacuvier and support the company's next phase of global growth. They come as ARIS advances its positioning around Process Context – giving AI agents the business understanding they need to operate effectively – while accelerating a product roadmap designed to help enterprises identify, deploy and scale AI ag
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 13:30:00 CEST | Press release
Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combinationArmenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance dataApprovals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastasesAgenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatell
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom